首页 | 本学科首页   官方微博 | 高级检索  
     

参附注射液治疗缓慢性心律失常的有效性和安全性研究:随机对照试验的系统评价和Meta分析
引用本文:章轶立,贾敏,谢雁鸣,廖星,王凤姣. 参附注射液治疗缓慢性心律失常的有效性和安全性研究:随机对照试验的系统评价和Meta分析[J]. 北京中医药大学学报, 2016, 39(7): 595-604. DOI: 10.3969/j.issn.1006-2157.2016.07.014
作者姓名:章轶立  贾敏  谢雁鸣  廖星  王凤姣
作者单位:中国中医科学院中医临床基础医学研究所 北京100700;中国中医科学院中医临床基础医学研究所 北京100700;中国中医科学院西苑医院;中国中医科学院中医临床基础医学研究所 北京100700;中国中医科学院博士后流动站;北京中医药大学第三附属医院
基金项目:#中央级公益性科研院所基本业务费项目(Z0406,PY1303),2014年第七批博士后特别资助(2014T70202)
摘    要:目的评价参附注射液治疗缓慢性心律失常的有效性及安全性。方法计算机检索中国期刊全文数据库、万方数据库、中文科技期刊数据库、中国生物医学数据库、Medline、EMbase、ClinicalTrials.gov,筛选出参附注射液治疗缓慢性心律失常的随机对照试验;用Cochrane协作网评价偏倚风险工具对纳入研究进行质量评价,Rev Man5.3软件进行Meta分析。结果共收集参附注射液治疗缓慢性心律失常文献99篇,经过初筛和严格评价,纳入13个研究,共978例,纳入文献质量普遍偏低,除一项研究为C级外,其他文献质量级别均为B级。总体疗效(临床症状或心率改善)方面,参附注射液优于阿托品(RR=1.27,95%CI 1.09~1.48,P=0.002),参附注射液联合阿托品较阿托品单用无统计学差异(RR=0.84,95%CI 0.73~0.97,P=0.30),参附注射液与极化液对比,可以更好改善临床症状(RR=0.52,95%CI 0.40~0.67,P=0.01);在心率改善方面无明显差异(RR=0.57,95%CI 0.32~1.20,P=0.06)。有4个研究报道了不良反应的发生,主要表现为口干舌燥等。结论鉴于目前的研究质量较低,尚不能肯定参附注射液在治疗缓慢性心律失常中的疗效,今后需更多高质量的研究以证实其疗效。

关 键 词:参附注射液  缓慢性心律失常  系统评价  循证医学

Efficacy and safety of Shenfu injection treating bradycardia:a systematic review with meta-analysis of randomized controlled trials
ZHANG Yili,JIA Min,XIE Yanming,LIAO Xing,WANG Fengjiao. Efficacy and safety of Shenfu injection treating bradycardia:a systematic review with meta-analysis of randomized controlled trials[J]. Journal of Beijing University of Traditional Chinese Medicine, 2016, 39(7): 595-604. DOI: 10.3969/j.issn.1006-2157.2016.07.014
Authors:ZHANG Yili  JIA Min  XIE Yanming  LIAO Xing  WANG Fengjiao
Abstract:Objective To evaluate the efficacy and safety of Shenfu injection in the treatment of brady-cardia.Methods Randomized controlled trials (RCT) on Shenfu injection treating bradycardiawas re-trieved from CNKI database, Wanfang Database,VIP Database,CBM,PubMed, EMbase, and Clinical Trials.gov.Cochrane Handbook was used to assess methodological quality , and data were analyzed using RevMan5 .3 Software .Results 13 trials involving 978 patients were included into the analysis .The over-all methodological quality was low as most studies were evaluated as B level and one study was C level . Meta-analysis showed that Shenfu injection was better than atropine (RR=1.27, 95%CI 1.09~1.48, P=0.002)in terms of the overall effect (relief of symptoms and improvement of heart rate ), but there were no statistic difference between using atropine alone andusing Shenfu injection and atropine together (RR=0.84, 95%CI 0.73~0.97, P=0.30).Compared with Shenfu injection in polarized solution, Shenfu injection can improve the clinical symptoms better (RR=0.52, 95%CI 0.40~0.67, P=0.01), but there was no difference in the heart rate increase (RR=0.57,95%CI 0.32 ~1.20,P=0.06). Safety:Adverse reactions were reported in four studies , with dry mouth being the most common one . Conclusion In view of the quality of the current research , the efficacy of treating bradycardia with Shen-fu injection cannot be ensured .In the future , high quality studies are needed to confirm the efficacy of Shenfu injection .
Keywords:Shenfu injection  bradycardia  systematic review  evidence-based medicine
本文献已被 CNKI 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号